Shire Nabs Advanced BioHealing Before It Can Test the Public Waters
This article was originally published in The Pink Sheet Daily
Executive Summary
Diversifying further, the specialty outfit will spend $750 million in cash for the regenerative medicine firm and its marketed wound-healing cell therapy product.
You may also be interested in...
Radius Raises $91 Million, Moves Toward Public Listing
Just two years ago Radius Health Inc. had a straightforward partnering strategy for its osteoporosis drug, BA058. Now that a key partner has opted not to exercise its option on the compound, Radius has instead raised a massive new round of funding that allows the company to keep full ownership of the compound. In addition, the crafting of a creative exit strategy alongside the financing paves a path to liquidity for its shareholders.
Radius Takes $91MM To Support Osteoporosis Drug, Moves Toward Public Listing
Five new investors back the owner of anabolic bone therapy BA058, while a reverse merger paves the way to the public markets.
Radius Takes $91MM To Support Osteoporosis Drug, Moves Toward Public Listing
Five new investors back the owner of anabolic bone therapy BA058, while a reverse merger paves the way to the public markets.